Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease

Matteo Cotta Ramusino, Valentina Garibotto, Ruggero Bacchin, Daniele Altomare, Alessandra Dodich, Frederic Assal, Aline Mendes, Alfredo Costa, Michele Tinazzi, Silvia D Morbelli, Matteo Bauckneht, Agnese Picco, Massimo E Dottorini, Cristina Tranfaglia, Lucia Farotti, Nicola Salvadori, Davide Moretti, Giordano Savelli, Anna Tarallo, Flavio NobiliMaura Parapini, Carlo Cavaliere, Elena Salvatore, Marco Salvatore, Marina Boccardi, Giovanni B Frisoni

Research output: Contribution to journalArticlepeer-review


PURPOSE: To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm.METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker.RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P 
Original languageEnglish
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Publication statusPublished - Aug 6 2019


Dive into the research topics of 'Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this